TP53 and hepatocellular carcinoma: Next, to evaluate whether GILncSig is better than TP53 mutation status predicting HCC prognosis, we divided all patients into TP53 mutation/GS, TP53 mutation/GU, TP53 wild/GS, and TP53 wild/GU groups.